Liver cancer breakthrough? study tests surgery vs. drug maintenance after successful initial therapy

NCT ID NCT07410715

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the cancer from coming back and helps patients live longer. Researchers will track outcomes like recurrence and survival over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1/PD-L1 inhibitor ± tyrosine kinase inhibitor (TKI)
What this could lead to: If successful, this study could show whether surgery or continued medication is better for liver cancer patients who improved after initial therapy, guiding future treatment decisions.
What could go wrong: This is a non-randomized study with only 100 participants, so results may not apply to all patients. The best approach may depend on individual factors not fully captured here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA SURGERY WATCH & WAIT

More trials for these conditions

Other studies related to the condition(s) this trial covers.